Wendy Kan

Counsel

Disclaimer

Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

Wendy Kan focuses her practice on corporate finance and capital markets. Her experience includes advising on Hong Kong initial public offerings, cross-border mergers and acquisitions, regulatory compliance, and general commercial matters.

Languages

  • Mandarin Chinese
  • Cantonese

Admissions

Bar Admissions

  • Hong Kong

Education

  • University of Hong Kong, PCLL; LLB

Professional Activities

Member

  • Hong Kong Law Society

ECM Transactions

  • Beauty Farm Medical and Health Industry Inc. in its approximately US$100 million IPO and listing on the Hong Kong Stock Exchange
  • Cryofocus Medtech (Shanghai) Co., Ltd. in its IPO and listing on the Hong Kong Stock Exchange
  • OrbusNeich Medical Group in its US$62 million IPO and listing on the Hong Kong Stock Exchange
  • Jenscare Scientific Co., Ltd. in its IPO and listing on the Hong Kong Stock Exchange
  • RemeGen in its approximately US$412 million A-share IPO and listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange
  • Shanghai Bio-heart Biological Technology Co., Ltd. in its US$65.3 million IPO and listing on the Hong Kong Stock Exchange
  • OrbusNeich Medical Group in its US$200 million Series A and A-2 Fundraising Rounds
  • Goldman Sachs (Asia) L.L.C. and China International Capital Corporation Hong Kong Securities Limited and other underwriters in the US$145 million IPO and listing of Shanghai HeartCare Medical Technology Corporation Limited on the Hong Kong Stock Exchange
  • Brii Biosciences Limited in its US$318 million IPO and listing on the Hong Kong Stock Exchange
  • Keymed Biosciences Inc. in its US$398 million IPO and listing on the Hong Kong Stock Exchange
  • Fortune Financial Capital as sole sponsor, Fortune Securities, CICC as joint global coordinators and other underwriters in the US$56.8 million primary listing of Zero2IPO Holdings Inc. on the Hong Kong Stock Exchange
  • JACOBIO Pharmaceuticals Group Co., Ltd. in its US$174 million IPO and listing on the Hong Kong Stock Exchange
  • RemeGen Co., Ltd. in its US$515 million IPO and listing on the Hong Kong Stock Exchange
  • Honliv Healthcare Management Group Company Limited in its US$41.3 million IPO and listing on the Hong Kong Stock Exchange
  • Peijia Medical Limited in its US$343 million IPO and listing on the Hong Kong Stock Exchange
  • Shanghai Kindly Medical Instrument Co., Ltd., in its US$106 million IPO and listing on the Hong Kong Stock Exchange
  • Pharmaron in its approximately US$588 million dual primary listing and H share offering in Hong Kong
  • China Securities (International) Corporate Finance Company Limited, as the sole sponsor and lead underwriter, in the US$133 million IPO of mobile game publisher FingerTango Inc.(6860.HK) on the Hong Kong Stock Exchange
  • China Securities (International) Corporate Finance Company Limited, as the sole sponsor and lead underwriter, in the US$40 million IPO of mobile game publisher Digital Hollywood Interactive Limited (2022.HK) on the Hong Kong Stock Exchange
  • Dexin China Holdings Company Limited (2019.HK) in its US$190 million IPO and listing on the Hong Kong Stock Exchange
  • Shanghai Haohai Biological (6826.HK) in its US$300 million IPO and listing on the Hong Kong Stock Exchange
  • Phoenix Healthcare Group Co. Ltd. in its HK$1.5 billion (US$190 million) IPO on the Main Board of the Hong Kong Stock Exchange
  • Hengxing Gold Holding Company Limited in its HK$330 million (US$42.3 million) IPO on the Main Board of the Hong Kong Stock Exchange
  • Representing a Beijing based hospital group in its proposed listing on the Main Board of the Hong Kong Stock Exchange
VIEW MORE

In the News

Press Releases